Healx: The Cambridge AI Startup Hunting Cures for Rare Diseases Hiding in Plain Sight

Back to: Top 10 British Startups 2026

There are approximately 7,000 rare diseases affecting an estimated 300 million people worldwide. For the vast majority, there is no approved treatment. The economics of traditional pharmaceutical development — which requires hundreds of millions of pounds invested over a decade or more with no guarantee of approval — simply do not work for diseases affecting fewer than a few thousand patients. Healx, a Cambridge company founded in 2014, has dedicated itself to changing this equation by using artificial intelligence to find new treatments for rare diseases within the vast existing landscape of approved drugs.

Company Overview

Healx was co-founded by Tim Guilliams and David Brown, combining academic expertise in machine learning with deep experience in pharmaceutical development. The company is based in Cambridge, embedded within the ecosystem of biotech and pharma expertise that has made the city one of the world's leading centres for life sciences research. Its platform, HealNet, integrates genomic data, clinical trial data, published research literature, and real-world evidence to identify patterns suggesting that existing drugs might be effective for rare diseases they were never designed to treat.

This drug repurposing approach has significant advantages over traditional drug discovery. Repurposed drugs have already demonstrated safety in human subjects, dramatically reducing the risk and duration of clinical development. Regulatory pathways for repurposed drugs are generally faster and cheaper. And the universe of potential repurposed compounds is vast — with thousands of approved drugs whose full therapeutic potential has never been systematically explored, HealNet's ability to identify promising candidates at scale represents a genuine competitive advantage over both traditional pharmaceutical research and competing computational approaches.

Business Model

Healx operates a hybrid business model combining internal drug development with partnerships with pharmaceutical companies and patient advocacy organisations. In its internal development pipeline, the company identifies drug-disease matches through HealNet, validates them in laboratory and animal models, and advances the most promising candidates into clinical trials. In its partnered work, Healx licences its platform and discovery capabilities to pharmaceutical companies seeking to maximise the value of their existing drug portfolios or identify repurposing opportunities for compounds that failed in their original indications.

The partnership model has proven particularly fruitful, generating significant non-dilutive revenue through upfront fees, milestone payments, and royalty agreements. Several of these partnerships have advanced candidate compounds into clinical development, providing both validation of the HealNet platform and concrete evidence of the company's ability to move from computational prediction to clinical reality — the critical credibility gap that all AI-powered drug discovery companies must cross to attract serious investment and partnership interest.

Innovation Factor

HealNet's technical innovation lies in its ability to synthesise extraordinarily heterogeneous data types — structured genomic databases, unstructured clinical literature, real-world treatment records, and molecular interaction networks — into a unified knowledge representation that can be queried for drug repurposing signals. The machine learning models underpinning this integration have been developed and refined over nearly a decade, incorporating advances in graph neural networks, natural language processing, and multi-modal learning that have transformed the field during the period of Healx's existence.

The company's clinical validation programme is equally important to its innovation story. Computational predictions are valuable only if they translate into clinical reality, and Healx has invested heavily in the experimental biology capabilities needed to test HealNet's predictions before committing to clinical trials. This integrated approach — computational prediction followed by systematic experimental validation — has produced a pipeline quality that is demonstrably superior to companies that rely on computational output alone.

Market Position

Healx operates in a space — AI-powered drug discovery for rare diseases — where it has no direct commercial competitors of comparable maturity. The major pharmaceutical companies are active in rare disease research but operate through traditional discovery approaches; pure AI drug discovery companies like Exscientia and Recursion Pharmaceuticals focus primarily on common diseases where the commercial return is larger. Healx's specific focus on rare diseases gives it a distinctive positioning and access to a patient community that is uniquely motivated and well-organised. See also: Ori Biotech's cell therapy manufacturing and Graphcore's AI computing.

What's Next

Healx is advancing multiple candidate compounds through clinical development, with the most mature programmes targeting rare neurodevelopmental conditions including Fragile X syndrome and Tuberous Sclerosis Complex. Success in any one of these trials would be transformative — both for the patients who stand to benefit and for Healx's commercial prospects. Visit healx.io to learn more.